Iran-made nanodrug revolutionizes cancer diagnosis, treatment

An Iranian knowledge-based company has successfully developed an advanced nanodrug, Tilmanocept, which significantly enhances the accuracy of cancer diagnosis while reducing costs. 

According to the Communications and Information Center of the Vice Presidency for Science, Technology, and Knowledge-Based Economy, the breakthrough offers a more affordable and precise diagnostic and treatment method for approximately 90% of cancer patients in Iran. 

Aprin Sama Pharmed has produced the active ingredient for the diagnostic radiopharmaceutical Technetium, making Iran the second country in the world to master this advanced cancer detection technology. 

Tilmanocept, as the drug is known, marks a major step forward in cancer diagnosis and treatment, potentially transforming the landscape of cancer care by lowering diagnostic expenses. 

After successfully completing pre-clinical trials, the drug has entered the clinical phase. 

Unlike other radiopharmaceuticals, which are typically limited to specific cancer types, Tilmanocept can scan the entire lymphatic system, making it applicable to a wide range of cancers. 

Previously, the production of the radiopharmaceutical was exclusive to the US since 2013. 

The advancement not only enhances the quality of life for cancer patients but also elevates Iran’s standing in the global medical and nanotechnology sectors.